Acadia Pharmaceuticals has initiated its pivotal Phase 3 COMPASS PWS study of carbetocin nasal spray (ACP-101) in the United States. COMPASS PWS is a 12-week study evaluating the efficacy and safety of carbetocin nasal spray for hyperphagia in approximately 170 children and adults aged 5 to 30 years with Prader-Willi syndrome.
At this time, about 36 clinical study sites throughout the United States, Canada, and Europe are expected to participate in the Phase 3 COMPASS PWS study. Participants who complete the Phase 3 study will be eligible to enroll in a long-term, open-label extension study designed to investigate the safety and tolerability of long-term treatment with carbetocin nasal spray.
For more information on the COMPASS PWS study, including who can participate, you can visit the trial website at CompassPWS.com. The website also features a “Find a Research Site” tool which will be updated on an ongoing basis as trial sites are opened.
If you have questions about the carbetocin nasal spray Phase 3 study, you can contact Acadia at medicalinformation@acadia-pharm.com.
About Acadia Pharmaceuticals
Acadia is advancing breakthroughs in neuroscience to elevate life. For almost 30 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapies for hallucinations and delusions associated with Parkinson’s disease psychosis and for the treatment of Rett syndrome. Our clinical-stage development efforts are focused on treating the negative symptoms of schizophrenia, Prader-Willi syndrome, Alzheimer’s disease psychosis and neuropsychiatric symptoms in central nervous system disorders. For more information, visit us at www.acadia.com and follow us on LinkedIn and Twitter.
